Table 3. Duration from Drug Discontinuation to the Onset of Adverse Events.
| SAPT | No-APT | ||
|---|---|---|---|
| Median (IQR) days | Median (IQR) days | P value | |
| SES stratum | |||
| Definite ST | 949 (451–1731) | 36.5 (8–632) | <0.001 |
| Spontaneous MI | 749 (203–1392) | 277 (20–750) | 0.09 |
| Stroke | 519 (137–976) | 30 (7–124) | <0.001 |
| BMS stratum | |||
| Definite ST | 100 (37–640) | 18.5 (8–36) | 0.005 |
| Spontaneous MI | 721 (277–1327) | 473 (14–778) | 0.04 |
| Stroke | 625 (222–1141) | 44 (5–840) | 0.001 |
Duration of SAPT is the number of days from the last day when patients received DAPT to the day of adverse event, without any consideration for days with no-APT in between, if any, for the patients who had adverse event on SAPT. Duration of no-APT is the number of consecutive days with no-APT just before the adverse event.
APT = antiplatelet therapy, BMS = bare-metal stents, DAPT = dual-APT, IQR = interquartile range, MI = myocardial infarction, SAPT = single-APT, SES = sirolimus-eluting stents, and ST = stent thrombosis.